PL429630A1 - Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparaty radiofarmaceutyczne oraz ich zastosowanie w diagnostyce raka prostaty - Google Patents

Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparaty radiofarmaceutyczne oraz ich zastosowanie w diagnostyce raka prostaty

Info

Publication number
PL429630A1
PL429630A1 PL429630A PL42963019A PL429630A1 PL 429630 A1 PL429630 A1 PL 429630A1 PL 429630 A PL429630 A PL 429630A PL 42963019 A PL42963019 A PL 42963019A PL 429630 A1 PL429630 A1 PL 429630A1
Authority
PL
Poland
Prior art keywords
radiopharmaceutical
derivatives
hynic
diagnosis
prostate cancer
Prior art date
Application number
PL429630A
Other languages
English (en)
Other versions
PL239934B1 (pl
Inventor
Arkadiusz Eugeniusz Sikora
Michał Maurin
Antoni Włodzimierz Jaroń
Justyna Pijarowska-Kruszyna
Monika Orzełowska
Barbara Janota
Marcin Radzik
Piotr Garnuszek
Original Assignee
Narodowe Centrum Badań Jądrowych Ośrodek Radioizotopów Polatom
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Narodowe Centrum Badań Jądrowych Ośrodek Radioizotopów Polatom filed Critical Narodowe Centrum Badań Jądrowych Ośrodek Radioizotopów Polatom
Priority to PL429630A priority Critical patent/PL239934B1/pl
Priority to US16/559,014 priority patent/US11426395B2/en
Priority to EP19199838.4A priority patent/EP3721907B1/en
Publication of PL429630A1 publication Critical patent/PL429630A1/pl
Publication of PL239934B1 publication Critical patent/PL239934B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Przedmiotem wynalazku są pochodne inhibitora PSMA-HYNIC o wzorze PSMA-L1-L2-HYNIC, hydrazonowe pochodne aromatyczne i alifatyczne, zestaw radiofarmaceutyczny do znakowania izotopem 99mTc, preparat radiofarmaceutyczny oraz zastosowanie przedmiotowych, ww. pochodnych do diagnostyki raka prostaty i przerzutów.
PL429630A 2019-04-12 2019-04-12 Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty PL239934B1 (pl)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL429630A PL239934B1 (pl) 2019-04-12 2019-04-12 Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty
US16/559,014 US11426395B2 (en) 2019-04-12 2019-09-03 PSMA inhibitor derivatives for labelling with 99mTc via HYNIC, a radiopharmaceutical kit, radiopharmaceutical preparations and their use in prostate cancer diagnostics
EP19199838.4A EP3721907B1 (en) 2019-04-12 2019-09-26 Psma inhibitor derivatives for labelling with 99mtc via hynic, a radiopharmaceutical kit, radiopharmaceutical preparations and their use in prostate cancer diagnostics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL429630A PL239934B1 (pl) 2019-04-12 2019-04-12 Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty

Publications (2)

Publication Number Publication Date
PL429630A1 true PL429630A1 (pl) 2020-10-19
PL239934B1 PL239934B1 (pl) 2022-01-31

Family

ID=68072127

Family Applications (1)

Application Number Title Priority Date Filing Date
PL429630A PL239934B1 (pl) 2019-04-12 2019-04-12 Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty

Country Status (3)

Country Link
US (1) US11426395B2 (pl)
EP (1) EP3721907B1 (pl)
PL (1) PL239934B1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111253465A (zh) * 2020-03-03 2020-06-09 复旦大学附属肿瘤医院 一种psma结合剂及其用途
CN115260155B (zh) * 2022-08-08 2023-11-10 北京师范大学 一种含三唑环和肼基尼古酰胺基的谷氨酸-脲衍生物及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3222615T3 (da) 2008-08-01 2022-06-20 Univ Johns Hopkins Psma-bindende stoffer og anvendelser deraf
SI4095130T1 (sl) 2013-10-18 2024-05-31 Novartis Ag Označeni zaviralci za prostato specifičnega membranskega antigena (PSMA), njihova uporaba kot kontrastna sredstva in farmacevtska sredstva za zdravljenje raka prostate
MX2016008466A (es) 2016-06-24 2017-12-25 Instituto Nac De Investigaciones Nucleares 99mtc-edda/hynic-ipsma como un radiofarmaco para la deteccion de la sobre-expresion del antigeno prostatico de membrana.

Also Published As

Publication number Publication date
PL239934B1 (pl) 2022-01-31
US20200324000A1 (en) 2020-10-15
US11426395B2 (en) 2022-08-30
EP3721907B1 (en) 2023-05-03
EP3721907A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
CO2019006787A2 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos
CY1123790T1 (el) Σημασμενοι me 18f αναστολεις του ειδικου προστατικου αντιγονου της μεμβρανης (psma) και χρηση τους ως απεικονιστικα μεσα για τον καρκινο του προστατη
BR112016010927A2 (pt) Conjugado de fórmula
PH12016500656A1 (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
BR112018074268A2 (pt) pastas dentais terapêuticas e métodos e kits relacionados
CL2016003301A1 (es) Compuestos derivados del ácido amino-(piridin-4-carboxílico) sustituidos, inhibidores de la histona desmetilasa; composición farmacéutica, que los comprende, útiles en el tratamiento del cáncer, tales como el cáncer de próstata, mama, vejiga, pulmón y/o melanoma.
MX2018008168A (es) Inhibidores de antigenos de membrana especificos de la prostata (psma) basados en la urea para imaginologia y terapia.
MA40074A (fr) Composés liant ras multivalents
MX2016014615A (es) Compuestos heterociclicos deuterados y su uso como agentes formadores de imagenes.
BR112015016585A2 (pt) Compostos radiofarmacêuticos baseados em triazina, complexos de metal e composição farmacêutica compreendendo os referidos complexos
CO2020005944A2 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos
BR112012018954A2 (pt) derivados de hetaril-[1,8]naftiridina
MX379367B (es) Kit para marcaje radiactivo con galio 68 (68ga) que comprende un inhibidor de metal.
BR112016001645A8 (pt) derivados de oxoquinazolinil-butanamida, seu uso, medicamentos e kit
CL2021002110A1 (es) Hidroxipiridoxazepinas como activadores de nrf2.
WO2014145257A3 (en) Activity-based probe compounds, compositions, and methods of use
LT3481804T (lt) Radioaktyviai pažymėto prostatos specifinio membranos antigeno (psma) inhibitoriaus [18f]dcfpyl pagerinta sintezė
MX2019001053A (es) Inhibidores de antigeno de la membrana especifico para la prostata (psma) quelados.
PL429630A1 (pl) Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparaty radiofarmaceutyczne oraz ich zastosowanie w diagnostyce raka prostaty
CY1113022T1 (el) Ακτινoφαρμακευτικες συνθεσεις οι οποιες περιεχουν πολυσακχαριτες εμβολιασμενους με πολυαμιδια
CR20110075A (es) Agentes antifúngicos
CO2020000231A2 (es) Composiciones inmunogénicas que comprenden cea muc1 y tert
BR112015023280A2 (pt) derivados de dihidroquinolin-2-ona para utilização como inibidores da aldosterona sintase
BR112016005897A2 (pt) derivado de triazina
MX2017008989A (es) Agente sensibilizador de tumores multirresistentes.